Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Clinical and Molecular Hepatology
>
2020
>
26
>
3
Volume:
26
Issue:
3
1. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Page:312—314
2. Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
Page:305—308
3. Is liver biopsy still useful in the era of non-invasive tests?
Page:302—304
4. Macro-aspartate aminotransferase in a healthy woman
Page:378—381
5. Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?
Page:315—317
6. Fecal microbiota transplantation in alcohol related liver diseases
Page:294—301
7. Management of liver diseases during the pandemic of coronavirus disease-19
Page:243—250
8. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
Page:309—311
9. Novel biomarkers for the management of chronic hepatitis B
Page:261—279
10. How does low-level viremia affect the prognosis of patients with chronic hepatitis B?
Page:376—377
11. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
Page:340—351
12. Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis
Page:280—293
13. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
Page:364—375
14. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Page:352—363
15. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Page:328—339
16. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years
Page:318—327
17. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Page:251—260